Anzeige
Mehr »
Login
Dienstag, 07.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Diese Aktie hebt ab: +130,67% Kursgewinn in 1 Monat – das sind die Gründe
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
59 Leser
Artikel bewerten:
(0)

Medicsight Announces New Marketing Partnership with INFINITT

NEW YORK, April 7, 2008 /PRNewswire-FirstCall/ -- Medicsight PLC, a subsidiary of MGT Capital Investments, Inc. , and an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists in the early detection and diagnosis of disease, announces a new global partnership with INFINITT, one of the world's leading medical imaging and picture archiving and communication systems (PACS) companies. Combined INFINITT-Medicsight products for the detection of colorectal cancer will be distributed using INFINITT's global network of offices in six strategic countries and partners and sales channel representatives in 20 other countries worldwide.

David Sumner, Chief Executive of Medicsight, said: "I am delighted to announce this new global partnership with INFINITT, already the PACS market leader in Korea and growing rapidly in other major markets. Strategic partnerships such as this one are a key component of our strategy to build a broad base distribution channel enabling the Company to penetrate global markets quickly and thereby move into profitability."

"This is the ideal time for INFINITT to partner with Medicsight," said Sun-Joo Lee, President and CEO of INFINITT. "The partnership will enable us to bring the next generation of INFINITT solutions combined with the CAD and image analysis solutions of Medicsight to meet the demanding needs of our global customers."

Dr. Se Hyung Kim, Assistant Professor, Department of Radiology, Seoul National University, also commented: "CT Colonography for the screening of colorectal cancer is now at the forefront of screening technologies for this potentially fatal disease. Partnerships such as that between Medicsight and INFINITT which deliver cutting edge 3D and CAD technologies to radiologists around the world are vital to increase the adoption of this very important and life saving technique."

Medicsight's ColonCAD(TM) software will be integrated into INFINITT's PACS and 3D Rapidia Virtual Colonoscopy workstations. The latter is a next- generation colorectal cancer screening tool. Integration has already commenced and a successful work-in-progress project was demonstrated at the Radiology Society of North America (RSNA) meeting in November 2007, the major radiology event of the year. Medicsight and INFINITT will work together to prepare for a 2008 global launch campaign.

About MGT Capital Investments, Inc.

MGT Capital Investments, Inc is a holding company that focuses on investments in the global healthcare information technology market. The Company has two subsidiaries, Medicsight PLC and Medicexchange PLC.

Medicsight PLC (AIM: MDST) is a leading developer of computer-aided detection (CAD) software solutions. Medicsight's CAD solutions help clinicians utilizing Computed Tomography (CT) scans to identify, measure and analyze suspicious pathology within the colon and lungs. The Medicsight CAD products are validated against one of the world's largest databases of verified CT scan data collected from leading healthcare institutions from around the world. Medicsight products allow radiologists and physicians to review scans more quickly and accurately -- saving both time and lives

Medicexchange PLC provides medical imaging professionals with a global web portal containing an online sales, jobs and information channel for diagnostic, treatment and surgery planning solutions. This combined with a variety of relevant clinical papers, training materials and content gives these professionals access to information and products that they otherwise would have difficulty accessing.

Additional information can be found at http://www.mgtci.com/. About INFINITT

INFINITT Co., Ltd. is one of the world's leading companies in medical imaging and information management. INFINITT, founded in 1997, develops, manufactures and markets PACS systems, 3D medical imaging workstations and imaging software that are now implemented in over 1000 medical institutions in 14 countries, making the company one of the fastest growing vendors in the global PACS industry. INFINITT is the market leader in the South Korea PACS market, and is aggressively pioneering worldwide market expansion through joint ventures in four strategic regions: Japan, China, Taiwan, and the US, with a branch office in Malaysia.

All forward-looking statements are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission.

Investor & Media enquiries: KCSA Strategic Communications Todd Fromer / Garth Russell Tel: +1 212-896-1215 / 212-896-1250tfromer@kcsa.com / grussell@kcsa.com

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2008 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.